$200 million ...

... in damages awarded to Merck & Co. by a federal jury in March for Gilead Sciences, Inc.'s alleged infringement on two Merck patents (for the hepatitis C drug sofosbuvir) were overturned recently by a federal district court judge who cited Merck's patent attorney for being "dishonest and duplicitous."